Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721874 | 0.82 | KMT2A (0.65) | KMT2ANPC1RAB9A | |
| SCHEMBL28734357 | 0.82 | KMT2A (0.65) | KMT2ANPC1RAB9A | |
| SCHEMBL13833371 | 0.81 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3711806 | 0.80 | RAB9A (0.73) | KMT2ANPC1RAB9A | |
| SCHEMBL29964652 | 0.79 | TSHR (0.65) | KMT2ARAB9A | |
| SCHEMBL29964657 | 0.79 | TSHR (0.65) | KMT2ARAB9A | |
| SCHEMBL2595484 | 0.79 | HDAC2 (0.55) | HDAC1HDAC2KMT2AHDAC3 | |
| SCHEMBL19575701 | 0.78 | NPC1 (0.52) | HDAC1HDAC2KMT2AHDAC3NPC1 | |
| Bicarbonate SCHEMBL19664773 | 0.77 | RAB9A (0.69) | KMT2ANPC1RAB9A | |
| SCHEMBL15765838 | 0.77 | ALDH1A1 (0.71) | KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| CN-101563327-A | Pyrimidine kinase inhibitors | GENENTECH INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2099771-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | DTYMK, DCK, TYMP | HDAC1 1855/4885HDAC2 1861/4885KMT2A 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.